Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Adolescent Medicine Specialists: Pediatricians

Articles with lock require a subscription to GLG News | Request a free trial
June 9, 2008
Could be a smart move or could backfire
Analysis of: Datacsope stock soars on takeover tlaks | www.northjersey.com
Author: GLG Expert Contributor
-Datascope has decided to exit the monitor market by selling a chunk of itself off, possibly making itself into a takeover candidate.  The remaining units make stents, balloon catheters and other cardiac equipment.  -One other effect is that it has placed itself into direct (rather than indirect)...
June 9, 2008
Pipeline or Preening for an Aquirer?
Analysis of: Novartis presents full pipeline of novel vaccines addressing significant unmet needs | www.pipelinereview.com
Author: GLG Expert Contributor
-Novartis' press conference discussed a "full pipline" of new vaccines, but the majority are still Phase I. -The meningitis vaccines being developed are not yet ready to go, and the one that is closest to being filed already has a competitor on the market.
June 2, 2008
Big opportunity for Glaxo
Analysis of: GlaxoSmithKline given OK to sell bird-flu vaccine in Europe | www.bizjournals.com
Author: GLG Expert Contributor
-Glaxo's pre-pandemic flu vaccine is a double opportunity - a chance to contract now with multiple governments to supply a pre-pandemic vaccine as well as a natural segue to become their future supplier of actual pandemic flu vaccine (when developed).  -When pandemic flu hits, the race will be...
May 21, 2008
GSK gets there first (for a change)
Analysis of: EU Approves GSK's Pre-Pandemic Bird Flu Vaccine | www.medicalnewstoday.com
Author: GLG Expert Contributor
Glaxo's new pandemic flu vaccine was just approved for sale and use in the EU.  It has or is trying to establish contracts with multiple countries to supply stockpiles with values in the 100's of millions
May 13, 2008
Lily's impact likely minimal
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
Strattera has been approved for "maintenance treatment" for ADHD, however this probably changes nothing for prescribers or patients.  Those who are on it will continue to take it, but no one will be changing to Strattera because of this new classification.
May 12, 2008
Will Strattera be around in 3 years?
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
My personal prediction is that this product will NOT be on the market in 3-5 years.  My clinical experience never approached that which the research would suggest.  I suspect that the "research" that was done on this product is frought with company incentives.
May 5, 2008
In Rotateq v. Rotarix, cost is only 1 issue
Analysis of: FDA Approves ROTARIX(R) Rotavirus Vaccine | www.pipelinereview.com
Author: GLG Expert Contributor
-Rotateq and Rotarix are the only two approved rotavirus vaccines in the US.  It's unclear how Rotarix will be priced, and since it is a 2-dose series vs. Rotateq's 3-dose series, the cost will be very important. -However, there are other factors as well, such as Merck being first to market...
April 7, 2008
Let the Rotavirus battle begin!
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Expert Contributor
-Glaxo's Rotarix vaccine was approved last week for prevention of rotavirus infection in infants -Merck's product, Rotateq, on the market for 2 years in the US, already has an established pipeline to essentially all pediatric primary care providers -There are small differences between the 2 vaccines,...
March 31, 2008
So it begins...
Analysis of: FDA Investigating Possible Link Between Singulair and Suicide | www.foxnews.com
Author: GLG Expert Contributor
-Reports of suicidality have been added to Mercks' PI for Singulair -The media have begun to report on this in the past few days and patients are already making calls to their docs -A la Vioxx, Singulair is poised to become the next whipping boy for every depressed asthmatic...
March 24, 2008
Sure, and let's buy them all a pony, too!
Analysis of: Vaccinating Boys for Girls’ Sake? | www.nytimes.com
Author: GLG Expert Contributor
Everyone who thinks that the FDA is going to license a vaccine as costly as Gardasil for boys is insane (sorry if I'm being too subtle). Girls get cervical cancer; the rates of penile and anal cancers from HPV is minuscule in comparison. The cost of Gardasil for girls alone is going to strain a...

Previous Page : 1 2 3 4 5 Next11 to 20 of 49

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203